ArticleCureus2025
Real-World Outcomes of Upfront Abiraterone in Metastatic Castration-Sensitive Prostate Cancer Patients at a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Metastatic castration-sensitive prostate cancer is defined as prostate cancer with de novo metastatic disease that responds to androgen deprivation therapy by keeping the testosterone levels low. Endogenous androgen synthesis is further blocked by abiraterone acetate along with prednisolone and indicated in patients with metastatic castration-sensitive prostate cancer. However, over time, these patients will become castration-resistant. The time from castration-sensitive to castration-resistant in our population is short, which calls for further investigation on a larger scale to explore factors such as genetics and environmental influences that may play a significant role. Methodology This retrospective study involved 47 adult patients aged 40 years and older. It focused exclusively on patients who were presented with de novo metastatic castration-sensitive disease and were treated with upfront abiraterone acetate. The study was carried out at the Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. Patient data spanning 10 years, from 2014 to 2024, was collected from hospital records. Results The cohort demonstrated a median progression-free survival (PFS) of 20.7 months and a median overall survival (OS) of 38.4 months. These outcomes represent the entire study population, irrespective of subgroup classification. Different subgroup analyses do not show any statistically significant difference. Conclusion In our study, OS and PFS were lower than those reported in landmark studies conducted on similar populations in Western countries. This disparity highlights the need for further research in subcontinental populations to investigate potential contributing factors, including environmental influences or genetic variations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.